| Literature DB >> 33172193 |
Yu-Chia Chang1, Chih-Chao Chiang2, Yuan-Shiun Chang3, Jih-Jung Chen4, Wei-Hsien Wang5, Lee-Shing Fang5,6,7, Hsu-Ming Chung8, Tsong-Long Hwang1,9,10,11,12, Ping-Jyun Sung5,13,14,15,16.
Abstract
Two previously undescribed caryophyllane-related sesquiterpenoids, antipacids A (1) and B (2), with a novel bicyclo[5.2.0] core skeleton, and known compound clovane-2β,9α-diol (3), along with rumphellolide L (4), an esterified product of 1 and 3, were isolated from the organic extract of octocoral Rumphella antipathes. Their structures, including the absolute configurations were elucidated by spectroscopic and chemical experiments. In vivo anti-inflammatory activity analysis indicated that antipacid B (2) inhibited the generation of superoxide anions and the release of elastase by human neutrophils, with IC50 values of 11.22 and 23.53 μM, respectively, while rumphellolide L (4) suppressed the release of elastase with an IC50 value of 7.63 μM.Entities:
Keywords: Rumphella antipathes; antipacid; caryophyllane; clovane; elastase; rumphellolide; superoxide anion
Mesh:
Substances:
Year: 2020 PMID: 33172193 PMCID: PMC7694975 DOI: 10.3390/md18110554
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of antipacids A (1) and B (2), clovane-2β,9α-diol (3), and rumphellolide L (4), and an image of Rumphella antipathes.
1H (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) NMR data of 1 and 2.
| 1 | 2 | |||
|---|---|---|---|---|
| C/H | δH ( | δC, Type | δH ( | δC, Type |
| 1 | 1.77 ddd (10.4, 10.4, 3.6) | 45.3, CH | 1.81 ddd (10.8, 10.8, 3.6) | 44.9, CH |
| 2a/b | 1.70 m; 1.64 m | 23.7, CH2 | 1.71 m; 1.62 m | 23.7, CH2 |
| 3a/b | 2.48 m; 2.41 m | 43.8, CH2 | 2.49 m | 43.7, CH2 |
| 4 | - | 212.8, C | - | 212.5, C |
| 5 | - | 179.1, C | - | - |
| 6 | 2.27 m | 29.3, CH2 | - | 176.0, C |
| 7a/b | 1.72 m; 1.53 m | 36.5, CH2 | 2.29 d (13.6); 2.28 d (13.6) | 44.7, CH2 |
| 8 | - | 35.0, C | - | 34.9, C |
| 9 | 1.87 ddd (10.4, 10.4, 8.0) | 46.3, CH | 1.98 ddd (10.8, 10.8, 8.4) | 46.2, CH |
| 10a/b | 1.57 dd (10.4, 8.0); 1.49 dd (10.4, 10.4) | 35.5, CH2 | 1.56 dd (10.8, 8.4); 1.48 dd (10.8, 10.8) | 34.9, CH2 |
| 11 | - | 34.4, C | - | 33.9, C |
| 12a/b | 2.35 d (11.2); 2.30 d (11.2) | 54.8, CH2 | 2.60 d (11.2); 2.49 d (11.2) | 54.1, CH2 |
| 13 | 0.92 s | 20.5, CH3 | 1.08 s | 21.2, CH3 |
| 14 | 1.01 s | 30.1, CH3 | 1.02 s | 30.1, CH3 |
| 15 | 1.01 s | 22.1, CH3 | 1.01 s | 22.1, CH3 |
Figure 2(A) Key COSY (), HMBC (), and (B) NOESY () correlations of 1.
Figure 3Key COSY (), HMBC (), and NOESY () correlations of 2.
Figure 41H NMR chemical shift differences Δδ (δS–δR) in ppm for the MPTA esters of 3.
1H (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) NMR data for 4.
| C/H | δH ( | δC, Type | C/H | δH ( | δC, Type |
|---|---|---|---|---|---|
| 1 | 1.77 m | 45.2, CH | 1´ | - | 44.5, C |
| 2 | 1.64 m | 23.6, CH2 | 2´ | 4.83 dd (8.8, 6.0) | 82.1, CH |
| 3a/b | 2.48 ddd (12.4, 7.6, 4.0); 2.39 m | 43.7, CH2 | 3´a/b | 1.78 dd (12.0, 6.0); 1.51 m | 44.3, CH2 |
| 4 | - | 212.2, C | 4´ | - | 38.0, C |
| 5 | - | 173.6, C | 5´ | 1.48 m | 50.3, CH |
| 6 | 2.21 t (7.6) | 29.8, CH2 | 6´ | 1.46 m | 20.8, CH2 |
| 7 | 1.73 m | 36.7, CH2 | 7´ | 1.40 m | 33.0, CH2 |
| 8 | - | 35.1, C | 8´ | - | 34.6, C |
| 9 | 1.87 ddd (10.8, 10.8, 8.4) | 46.4, CH | 9´ | 3.31 br s | 74.9, CH |
| 10 | 1.54 m | 35.5, CH2 | 10´a/b | 2.00 m; 1.65 m | 26.3, CH2 |
| 11 | - | 34.4, C | 11´ | 1.58 m | 27.3, CH2 |
| 12 | 2.31 s | 54.9, CH2 | 12´a/b | 1.53 m; 1.01 m | 35.4, CH2 |
| 13 | 0.90 s | 20.5, CH3 | 13´ | 1.05 s | 31.4, CH3 |
| 14 | 1.02 s | 30.1, CH3 | 14´ | 0.91 s | 25.3, CH3 |
| 15 | 1.00 s | 22.1, CH3 | 15´ | 0.94 s | 28.2, CH3 |
Figure 5Key COSY () and HMBC () correlations of 4.
Scheme 1Plausible biogenetic pathway of 1–4.
Inhibitory effects of sesquiterpenoids 1–4 on superoxide anion generation and elastase release by human neutrophils in response to N-Formyl-l-methionyl-l-leucyl-l-phenylalanine/ Cytochalasin B (fMLF/CB).
| Superoxide Anion | Elastase | |||
|---|---|---|---|---|
| Compound | IC50 (μM) a | Inh % b | IC50 (μM) a | Inh % b |
|
| - | 11.89 ± 5.13 | - | 13.69 ± 2.33 * |
|
| 11.22 | - | 23.53 | - |
|
| - | 22.92 ± 4.27 * | - | 35.33 ± 6.40 * |
|
| - | 19.57 ± 3.69 ** | 7.63 | - |
a Concentration necessary for 50% inhibition (IC50). b Percentage of inhibition (Inh %) at 10 μg/mL. Results are presented as means ± S.E.M (standard error of the mean) (n = 3). * p < 0.05, ** p < 0.01 compared with the control (solvent, dimethyl sulfoxide-DMSO).